EON: A Single-Arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Latest Information Update: 09 May 2023
At a glance
- Drugs Etigilimab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EON
- 04 May 2023 Planned End Date changed from 31 May 2023 to 31 Dec 2023.
- 04 May 2023 Planned primary completion date changed from 31 May 2023 to 31 Dec 2023.
- 05 Apr 2023 Status changed from recruiting to active, no longer recruiting.